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Some functions of the insulin receptor (insR) are assumed to be mediated by pertussis toxin-sensitive GJGo proteins. Here we have located 
G-protein-activator domains in the cytoplasmic region of the human insR. We searched the sequence of insR and found three candidate regions 
at residues 1039 1061, 1147-1168 and 1325-1345, referred to as ISRP1, ISRP2 and ISRP3, respectively. Among them, the Gi/Go-activating function 
was observed only in peptide ISRP3. ISRP1 specifically activated Gs, whereas ISRP2 had no effect on G proteins. ISRP2 and ISRP3 contained 
five of six autophosphorylated yrosine residues in insR. After tyrosine phosphorylation, ISRP2 showed specific Gcactivating function, and ISRP3 
potentiated its ability and became capable of activating G proteins generally. This is the first study that specifies G-protein-activator domains in 
insR and describes their modification by autophosphorylation. 
Insulin receptor; G-protein-activator sequence; Autophosphorylation 
1. INTRODUCTION 
Insulin is a polypeptide playing a key role in a variety 
of metabolic processes, including lucose uptake in var- 
ious cells and tissues. It exerts biological actions by 
binding to a specific receptor located on the surface of 
target cells [1,2]. Insulin also elicits mitogenic actions 
through this receptor in several kinds of cells. The insR 
(insulin receptor) is a membrane-bound glycoprotein, 
consisting of two ~ chains (each of ~ 135 kDa) and two 
fl chains (each of -~ 90 kDa). The a chain, located ex- 
tracellularly, binds insulin, and the fl chain, a major 
portion of which is located intracellularly, possesses an 
insulin-dependent tyrosine kinase function. Evidence 
has accumulated that insR-mediated tyrosine phospho- 
rylation conveys incoming information from insulin 
binding to specific subsets of intracellular effector pro- 
teins [3]. Although IRS1 of 185 kDa appears to be the 
only established substrate of insR kinase [4], several 
signaling pathways, such as the ras p21-c-fos expression 
system [5], the MAP kinase-mediated system [6], and the 
PI-3 kinase system [7], have been identified as specific 
targets of insR kinase. On the other hand, however, the 
physiological role of tyrosine phosphorylation triggered 
by the insulin/insR complex has been poorly defined, 
although its significance in insulin actions is clear. 
In addition to tyrosine phosphorylation, G-protein- 
mediated signal transduction is another candidate for 
*Corresponding author. Fax: (1) (617) 726-5806. 
insulin-triggered signaling pathways of insR. G proteins 
are guanine nucleotide-binding regulatory proteins that 
transmit signals from receptors to intracellular effectors 
such as enzymes and ion channels [8]. The GDP-bound 
form of G proteins is inactive for effector activation, 
and the GTP-bound form is active. In the unstimulated 
basal state, G proteins bind GDP. Receptors activate G 
proteins by stimulating the GDP/GTP exchange of G 
proteins. It has been reported that pertussis toxin inhib- 
its insulin-stimulated metabolic action as well as mito- 
genic action in intact cells [9-14]. Pertussis toxin ADP- 
r ibosy la tes  Gt, Gi, and Go and uncouples them from 
receptors [15]. Therefore, those reports uggest that per- 
tussis toxin-sensitive G proteins might be involved in 
insR-triggered signals. Yet, this does not directly imply 
that insR interacts with G proteins. The possibility re- 
mains that insR modulates other G-coupled receptor 
function via intracellular phosphorylation r via secre- 
tion of extracellular ligands, and thereby activates G- 
protein systems. In fact, it is reported that insR-induced 
phosphorylation alters the function offlAR (fl-adrener- 
gic receptor) [16]. 
However, in vitro studies have so far indicated that 
insR directly couples to G proteins. Heyworth et al. [17] 
reported that insulin attenuates ADP-ribosylation of a 
cholera toxin substrate, referred to as G~,s, in hepato- 
cyte membranes. Lutterel et al. [18] found that insulin 
promotes guanine nucleotide-binding to the membranes 
of BC3-H-1 myocytes, where they had earlier reported 
that pertussis toxin inhibits DNA synthesis and glucose 
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uptake promoted by insulin [10]. Similar findings have 
been reported using adipocytes [11-13,19]. It is also 
reported that in hepatocyte membranes, insulin attenu- 
ates the pertussis-toxin sensitivity of a 40-kDa Gi-like 
protein [20,21], suggesting that the insulin-bound insR 
activates the pertussis-toxin-sensitive G protein. Most 
recently, Jo et al. [22] reported that insR is directly 
associated with two proteins of 40 kDa and 67 kDa that 
bind GTP. Therefore, it is very important to address the 
question of whether insR possesses a mechanism 
whereby it is able to interact with G proteins directly. 
While receptors that couple to G proteins usually 
consist of a seven-transmembrane-domain structure 
[23], it has been proven that such a configuration is not 
essential for G-protein coupling. The IGF-IIR (insulin- 
like growth factor II receptor), a receptor with a single 
transmembrane domain, is demonstrated to couple di- 
rectly to Gi2 in a manner similar to that of conventional 
G-protein-coupled receptors [24,25]. We [26] discovered 
that IGF-IIR has a G~z-activator domain at residues 
2410 2423, which is RVGLVRGEKARKGK in the cy- 
toplasmic region of IGF-IIR. This region activates Gi2 
directly in the same manner as G-coupled receptors and 
is responsible for the Gi-coupling function of IGF-IIR 
in phospholipid vesicles. 
Based on the structure-function relationship of the 
IGF-IIR peptide, the structural characteristics for the 
Gi2-activating function were defined [26,27]. These char- 
acteristics served as the basis for identifying the Gs- and 
G~-activator regions in fl-adrenergic, muscarinic holin- 
ergic, and c~2-adrenergic receptors [28-30]. In the pres- 
ent study, we searched for regions atisfying these char- 
acteristics and found G-protein-activator regions in 
insR. We also noted that these functional domains were 
modified by tyrosine phosphorylation. 
3.0 
2.1. Materials 
The receptor polypeptides u ed in this study were synthesized by the 
solid phase method and purified to near homogeneity by high- 
performance liquid chromatography, as described previously [26]. The 
lyophilized synthetic polypeptides were dissolved in distilled water. 
The G proteins, which were trimeric forms purified from bovine brain 
and purified to homogeneity, were provided by Dr. Toshiaki Katada 
(Tokyo Institute of Technology, Japan) [31]. 
2.2. GTPyS binding assay 
GTPyS binding to G proteins was assayed at 37°C in the presence 
of 20/IM Mg 2+ and 60 nM [35S]GTPyS (DuPont-New England Nu- 
clear), as described previously [26,29]. GTPyS binding to polypeptides 
was negligible. The total amount of G proteins was measured as 
maximal GTPyS at room temperature. Binding of GTPTS to G pro- 
teins obeyed the law of first-order kinetics according to the equation 
In[(BI-B)IBT] = -k,  ppt, where B is the binding at time t and BT is the 
total binding observable at an infinite time. Thus, the apparent first- 
order rate constant for GTPyS binding (kapp)  , which is equal to the 
slope of the tangent to the GTPyS-binding curve at time 0 and repre- 
sents the actual GTPTS binding rate, was calculated from this equa- 
tion. The value of B was at 2 min for Go, 4 min for G~I, 5 min for Gi2, 
and 10 min for Gs. 
2.3. Phosphorylation of peptides 
The insulin receptor peptides ISRP2 and ISRP3 were phos- 
phorylated by p43 v-"b~ protein-tyrosine kinase (Oncogene Science) in 
buffer (50 mM HEPES/NaOH (pH 7.5), 0.1 mM EDTA, 0.015% 
polyoxyethylene 23 laruryl ether, 0.1 mM ATE 10 mM MgCI2) at 
30°C for 30 min. Reaction was stopped by adding 10% phosphoric 
acid solution. Phosphorylated peptides were purified by reverse phase 
HPLC using Cosmosil 5C18-P column with eluates of 10 60% gradi- 
ent concentrations of CH3CN , as described previously [28]. After 
lyophilization and immediately before experiments began, they were 
dissolved in distilled water. Experiments with 2 /tCi [y-32p]ATP 
showed that ~ 3 and 2 mol of phosphates were incorporated into one 
tool of ISRP2 and ISRP3, respectively. This suggests that all of the 
tyrosine residues contained in each peptide were phosphorylated. The 
phosphorylation efficiency (phosphopeptide/original peptide) was es- 
timated to be 0.8% for ISRP2 and 1.6% for ISRP3, respectively. 
3. RESULTS AND DISCUSSION 
The Gi-activator sequence first identified in native 
receptors is RVGLVRGEKARKGK, located at resi- 
dues 2410-2423 of human IGF-IIR [26]. This sequence 
requires the following two structural characteristics for 
its G~-activating function: (i) at least two basic residues 
at the N-terminal side and (ii) the C-terminal consensus 
structure, B-B-X-B or B-B-X-X-B (B = basic residue or 
aromatic residues, X= non-basic, non-aromatic resi- 
dues). In this study, we searched the primary sequence 
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Fig. 1. Effect of the insulin receptor peptide, ISRP1 on various G- 
proteins. By incubating G-proteins (G,, []; G~2, *; Go, D; Gs, ~') with 
peptide ISRPI (RERIEFLNEASVMKGFTCHHVVR, residues 
1039 1061 of human insulin receptor). GTP),S binding was assayed 
under the conditions described in section 2. The GTP?,S binding rate 
was assessed as the rate constant, kavp, and the extent of stimulation 
was expressed as the degree of stimulation of the rate constant relative 
to the basal rate. The method used for calclation is described in section 
2. The basal values of kapp were 0.113 + 0.05 for G~, 0.102 + 0.05 for 
G,2, 0.222 + 0.05 for Go, and 0.028 + 0.00l for G~ (min -1, mean 
+ S.E.M., n = 3) at these experiments. 
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Fig. 2. Effect of the insulin receptor peptide, ISRP2 on various G- 
proteins. By incubating G proteins (G~, D; Giz, *; G~, ,I) with peptide 
ISRP2(K IGDFGMTRDIYETDYYRKGGK,  residues 1147 1168of 
human insulin receptor), GTPTS binding was assessed as in the figure 
legend 1. The basal values of kap  were essentially the same as those 
in the Fig. 1 experiment. 
of human insR within 26 residues that satisfy these 
structural characteristics, as we did in our previous 
study [28-30]. Three criteria-satisfying regions were 
found in human insR at residues 1039-1061, 1147- 
1168, and 1325-1345 (numbering according to Ebinal 
et al. [1]). They are referred to as ISRP1, ISRP2, and 
ISRP3, respectively. 
We chemically synthesized ISRP1, ISRP2, and 
ISRP3. ISRP1 showed remarkable promotion of the 
rate of GTPT"S binding to Gs (Fig. 1). This peptide had 
little effect on other G proteins, Gi~, Gi2, o r  G o. The 
ECs0 of Gs-activating function of ISRP1 was 4/IM, and 
the saturated effect on Gs was observed at ~ 10 ¢tM. 
When its concentration exceeded 30 tiM, the effect of 
the peptide was attenuated, which was attributed to 
denaturation of the G protein after strong stimulation, 
as described [32]. Although the Arg259-Lys273 region of 
,BAR has a higher potency in the activation of Gs, it also 
activates Gi [28]. The Argl31~rg ~48 region in the second 
intracellular loop of c~2AR has been the most selective 
activator for Gs, but with 10-times lower potency than 
ISRP1 [29]. Thus, at present, ISRP1 is the most potent, 
G~-selective G-protein-activator peptide. In contrast, 
ISRP2 had negligible action on GTP),S binding to any 
G protein tested (Fig. 2), whereas it appeared to have 
a very weak but significant function to activate Gi. 
ISRP3 showed a strong activity to activate G~ and Go, 
and weak action on G~ (Fig. 3). The rate constant of 
GTPyS binding to Go was saturated once by 1 ¢tM 
ISRP3, further accelerated by -> 10 ¢tM of the peptide, 
and reached another saturation at 100 ¢tM. Although 
our Go consisted of a single band in silver staining (data 
not shown), this may suggest hat our Go preparation 
contained two different isoforms of Go, each of which 
responded ifferently to ISRP3 peptide. 
These results demonstrate hat insR possesses at least 
two G-protein-activator domains in its intracellular 
portion. The ISRP1 domain at residues 1039-1061 has 
a specific function to activate Gs, and the ISRP3 domain 
at residues 1325-1345 has a Gi/Go-activating function. 
The inability of the ISRP2 domain at residues 1147- 
1168 to activate G proteins provides evidence that not 
all regions possessing similar structure can activate G 
proteins, showing the action specificity of both ISRP1 
and ISRP3. Although extensive studies have suggested 
the functional linkage of insR with G proteins, espe- 
cially Gi proteins, this is the first report identifying the 
G-protein-activator domains in insR. 
Pertussis toxin-sensitive G proteins, which belong to 
the Gi/Go subclass, are the most likely G proteins to be 
linked with insR functions. This toxin attenuates some 
of the insulin effects, including glucose uptake [9 14]. 
In hepatocyte membranes, insulin causes a change in a 
40-kDa Gi-like protein [20,21], which can be recognized 
by reduction in pertussis toxin-catalyzed ADP-ribosyla- 
tion. Insulin promotes the binding of GTP analogs to 
myocyte and adipocyte membranes [18,19]. InsR is di- 
rectly associated with a Gi protein of 40 kDa [22]. An- 
other line of evidence comes from the altered function 
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Fig. 3. Effect of the insulin receptor peptide, ISRP3 on various G- 
proteins. By incubating G proteins (G~, [3; G~2, *; Go, ,I; G~, o) with 
peptide ISRP3 (KRSYEEHIPYTHMNGGKKNGR,  residues 1325- 
1345 of human insulin receptor), GTPyS binding was assessed as in 
the Fig. 1 legend. The basal values of k,pp were essentially the same 
as those in the Fig. 1 experiment. 
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Fig. 4. Modulation by phosphorylation of the effects of ISRP2 and ISRP3 on G-proteins. By incubating G-proteins (G0, left; Go, middle; G,2, right) 
with 10/zM of ]SRP2 or phosphorylated ISRP2, GTPyS binding was assayed. The GTPyS binding rate was assessed as the rate constant kap  (shown 
in the right vertical axis) and the extent of stimulation was expressed as the degree of stimulation of  the rate constant relative to the basal rate 
(shown in the left vertical axis) as described in the Fig. l legend, 
of Gi in diabetes, where abolished effects of insulin on 
Grlike proteins have been documented [33]. It has also 
been reported that the Gi function is impaired in liver 
membranes of animals with experimentally induced ia- 
betes [34-37]. These suggest that some metabolic effects 
of insR may be mediated by Grlike proteins. These 
findings are consistent with the present result, which 
shows that insR possesses a region (the ISRP3 region) 
that encodes a strong GJGo-activating function. 
In contrast, the data indicating that this receptor con- 
tains a region (the ISRP1 region) that encodes G~-acti- 
vating function were unexpected. There has been no 
evidence that insR activates Gs. It is very unlikely that 
insR stimulates adenylate cyclase, whereas this receptor 
lowers cAMP via cAMP phosphodiesterase stimulation 
[38]. However, there is still a possibility that insR acti- 
vates Gs or Gs-like proteins. In liver membranes, insulin 
activates PPM-PDE (peripheral plasma membrane 
cAMP phosphodiesterase), which is identical to the en- 
zyme stimulated by cholera toxin [39]. Cholera toxin is 
known to act on Gs and keep it in an active state [8]. 
Therefore, this provides a view that insR may activate 
Gs. However, this view has been controversial, for the 
following reasons [38]. First, insulin does not increase 
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cAMP levels in hepatocytes. Second, glucagon cannot 
activate PPM-PDE, despite the fact that this hormone 
activates adenylate cyclase. Third, dibutyryl cyclic 
AMP fails to activate PPM-PDE. 
One simple interpretation would be that insulin regu- 
lation of PPM-PDE is mediated by a unique cholera 
toxin-sensitive G protein, which is similar but distinct 
from Gs. On the other hand, there is another interpreta- 
tion, which refers to compartmentalization of Gs. Jou- 
neaux et al. [40] reported that calcitonin, parathyroid 
hormone, and glucagon each inhibit calcium pump ac- 
tivity in liver membranes, whereas these hormones do 
not stimulate adenylate cyclase. In contrast, isoprotere- 
nol does not inhibit the calcium pump, whereas it acti- 
vates adenylate cyclase. Genetically translated Gs~ 
showed both functions, decreasing calcium pump activ- 
ity and increasing adenylate cyclase activity. Based on 
these findings, Jouneaux et al. concluded that receptor- 
induced Gs signal is compartmentalized in liver mem- 
branes. This hypothesis makes it possible to speculate 
that PPM-PDE is exclusively stimulated by Gs compart- 
mentalized for insR. If insR couples to G~, it is highly 
likely that the ISRP1 region is responsible for this func- 
tion of insR, because ISRP1 is the most potent, Gs- 
selective G-protein-activator peptide. Even if insR cou- 
ples to Gs-like proteins other than G~, the G-protein- 
activating function of ISRP1, as assessed with purified 
Gs, would represent this activity. 
ISRP2 and ISRP3 contain almost all important Tyr 
residues, except Tyr 960, that receive autophosphoryla- 
tion (Tyr j158, Tyr 1162, Tyr 1163 in ISRP2, and Tyr 1328, 
Tyr 1334 in ISRP3). This prompted us to examine the 
effect of tyrosine phosphorylation  the G-protein- 
activator activity of ISRPs (Fig. 4). After tyrosine phos- 
phorylation of ISRP2, the function of this peptide to 
activate Gi was enhanced; its activity at 10 pM was 
promoted from 1.1-fold stimulation to 1.9-fold stimula- 
tion. The G~-activating activity was as low as that of 
non-phosphorylated ISRP2. The Go-stimulating activ- 
ity was slightly enhanced (from 1.3-fold stimulation to 
1.5-fold stimulation). Therefore, ISRP2 peptide ac- 
quired the ability to activate G~ by tyrosine phosphoryl- 
ation. In contrast, after phosphorylation, the G-pro- 
tein-activating functions of ISRP3 were enhanced for all 
of Gs, Gi and Go. The Gi2-activating function was ~ 2 
times enhanced (from 1.9-fold stimulation to 3.9-fold 
stimulation) and the Go-activating one was ~ 3 times 
enhanced (from 1.5-fold stimulation to 4.5-fold stimula- 
tion). It is most remarkable that ISRP3 became capable 
of activating Gs only after phosphorylation. Phospho- 
rylation thus conferred on ISRP2 the ability to activate 
Gi, and endowed ISRP3 with the ability to activate 
multiple classes of G proteins. These results, based on 
a non-receptor tyrosine kinase, may be preliminary. 
However, our findings open the novel possibility that 
tyrosine autophosphorylation d es play a role in ampli- 
fying the functions of the subdomains in insR. 
Pertussis toxin inhibits insulin-induced diacylglycerol 
production [10]. Whereas hydrolysis of PIP 2 is not acti- 
vated by insulin, hydrolysis of PI-glycan, which results 
in diacylglycerol production, is stimulated by insulin in 
an ATP-Mn2*-dependent manner [41], suggesting that 
this action requires insR kinase activity. Therefore, it is 
likely that Gi-like proteins mediate the InsR-induced 
PI-glycan hydrolysis, which is supported by insR ki- 
nase. This is consistent with the present finding that the 
Gi-activating function of the G-protein-activator do- 
mains in insR is enhanced when they undergo phospho- 
rylation. 
The notion that tyrosine autophosphorylation ampli- 
fies the functions of G-protein-activator domains of 
insR itself provides a new insight into additional roles 
of insR kinase in insR signaling pathways. It has been 
speculated that insR transmits insulin signals by phos- 
phorylating downstream olecules. However, it is sug- 
gested here that insR kinase may also play a role in 
enhancing the G-protein-activating function of insR 
subdomains. If such an enhancement by phosphoryla- 
tion is essential for sufficient signal generation by those 
domains in insR, kinase-deficient i sR should result in 
an inability to generate its own signals through those 
domains. Such concept would reconcile the apparently 
conflicting data, one showing the involvement of insR 
kinase activity in glucose uptake [3] and another show- 
ing the involvement of pertussis toxin-sensitive G pro- 
teins in the same output of insR [10]. 
For another example, it is reported that insulin treat- 
ment of cells rapidly desensitizes flAR from adenylate 
cyclase without down-regulation f flAR through insR 
kinase activity [16]. The conventional view would sug- 
gest that insR phosphorylates the flAR-Gs-adenylate 
cyclase-protein kinase A system, and attenuates flAR 
response. However, the data outlined here provide an- 
other possibility: insR may potentiate its own G~-acti- 
vating activity through its kinase function, resulting in 
rapid antagonism against flAR-induced stimulation of 
adenylate cyclase. 
The fact that insR encodes domains whose function 
is different from tyrosine kinase would lead us to use 
caution in interpreting the results gained from receptor 
mutagenesis. Some of the mutations nullifying the insR 
kinase may also perturb the domains on the insR fl 
chain which have specific functions to interact with G 
proteins. This logic is also applicable to insR mutations 
found in patients with genetic resistance to insulin. For 
example, the Met ~ 153 of insR is mutated to lie in patients 
with such resistance [42]. This mutation is known to 
reduce tyrosine kinase activity [42], whereas this Met 
residue is also included in the ISRP2 region. The possi- 
bility must therefore be considered that this mutation 
may also cause abnormality in insR-G-protein i terac- 
tions. 
As yet, functional reconstitution f purified insR with 
purified G proteins has not been accomplished. This is 
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in part because it is difficult to incorporate 0~2~ 2 of c~fl 
forms of insR into phospholipid vesicles. On the other 
hand, methods to antagonize the action of Gi/Go pro- 
teins more specifically than is possible with pertussis 
toxin have recently have developed, including the use of 
antibodies [43] and anti-sense RNAs [44] specific 
against G-protein-subunits. Furthermore, co-im- 
munoprecipitation f receptors and G proteins by anti- 
receptor or anti-G-protein antibodies has proven to be 
useful in demonstrating receptor coupling with specific 
G proteins [4547]. Using these advanced techniques, 
insR-G-protein coupling and its physiological signifi- 
cance may soon be clarified. 
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